Chames Patrick, Kerfelec Brigitte, Baty Daniel
INSERM U624, GDR2352, Marseille Cedex, France.
ScientificWorldJournal. 2010 Jun 15;10:1107-20. doi: 10.1100/tsw.2010.103.
Pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower than 5%. In the U.S., this disease is the fourth leading cause of death and represents 6% of all cancer-related deaths. Gemcitabine, the current standard first-line treatment, offers marginal benefits to patients in terms of symptom control and prolongation of life. Since 1996, about 20 randomized phase III trials have been performed to improve the efficacy of gemcitabine, with little success regarding a significant improvement in survival outcomes. The need for novel therapeutic strategies, such as target therapy, is obvious. Monoclonal antibodies have finally come of age as therapeutics and several molecules are now approved for cancer therapies. This review aims to give a general view on the clinical results obtained so far by antibodies for the treatment of pancreatic cancer and describes the most promising avenues toward a significant improvement in the treatment of this frustrating disease.
胰腺癌是一种极具毁灭性的疾病,死亡率极高,总体5年生存率低于5%。在美国,这种疾病是第四大死因,占所有癌症相关死亡的6%。吉西他滨作为目前的标准一线治疗药物,在症状控制和延长生命方面给患者带来的益处有限。自1996年以来,已经进行了约20项随机III期试验以提高吉西他滨的疗效,但在显著改善生存结果方面收效甚微。显然需要新的治疗策略,如靶向治疗。单克隆抗体最终成为了治疗药物,目前有几种分子已被批准用于癌症治疗。本综述旨在对目前抗体治疗胰腺癌所取得的临床结果进行总体概述,并描述在显著改善这种令人沮丧的疾病治疗方面最有前景的途径。